Cargando…

Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study

We performed a prospective study to examine the genetic effect on the response to a calcium (Ca) channel blocker, azelnidipine and an ACE inhibitor, temocapril treatment in patients with hypertension, as a part of the prior clinical trial, the Azelnidipine and Temocapril in Hypertensive Patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugimoto, Ken, Katsuya, Tomohiro, Kamide, Kei, Fujisawa, Tomomi, Shimaoka, Izumi, Ohishi, Mitsuru, Morishita, Ryuichi, Ogihara, Toshio, Rakugi, Hiromi
Formato: Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958339/
https://www.ncbi.nlm.nih.gov/pubmed/20981351
http://dx.doi.org/10.4061/2010/196307
_version_ 1782188321290584064
author Sugimoto, Ken
Katsuya, Tomohiro
Kamide, Kei
Fujisawa, Tomomi
Shimaoka, Izumi
Ohishi, Mitsuru
Morishita, Ryuichi
Ogihara, Toshio
Rakugi, Hiromi
author_facet Sugimoto, Ken
Katsuya, Tomohiro
Kamide, Kei
Fujisawa, Tomomi
Shimaoka, Izumi
Ohishi, Mitsuru
Morishita, Ryuichi
Ogihara, Toshio
Rakugi, Hiromi
author_sort Sugimoto, Ken
collection PubMed
description We performed a prospective study to examine the genetic effect on the response to a calcium (Ca) channel blocker, azelnidipine and an ACE inhibitor, temocapril treatment in patients with hypertension, as a part of the prior clinical trial, the Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study (ATTEST). Methods and Results. All subjects who gave informed consent for genetic research were divided into two groups: the subjects treated with azelnidipine or temocapril, for 52 weeks. We selected 18 susceptible genes for hypertension and determined their genotypes using TaqMan PCR method. RNA samples were extracted from peripheral blood, and quantitative real time PCR for all genes was performed using TaqMan method. One of the polymorphisms of the RGS2 gene was extracted as being able to influence the effect of these treatments to reduce BP. At eight weeks, BP change showed a significant interaction between the A-638G polymorphism of Regulator of G protein signaling-2 (RGS2) gene and treatment with azelnidipine or temocapril. There was no gene whose expression was associated with BP phenotypes or the polymorphisms of each gene. Conclusions. A-638G polymorphism of the RGS-2 gene could be a predictive factor for therapeutic performance of Ca channel blockers.
format Text
id pubmed-2958339
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher SAGE-Hindawi Access to Research
record_format MEDLINE/PubMed
spelling pubmed-29583392010-10-27 Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study Sugimoto, Ken Katsuya, Tomohiro Kamide, Kei Fujisawa, Tomomi Shimaoka, Izumi Ohishi, Mitsuru Morishita, Ryuichi Ogihara, Toshio Rakugi, Hiromi Int J Hypertens Research Article We performed a prospective study to examine the genetic effect on the response to a calcium (Ca) channel blocker, azelnidipine and an ACE inhibitor, temocapril treatment in patients with hypertension, as a part of the prior clinical trial, the Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study (ATTEST). Methods and Results. All subjects who gave informed consent for genetic research were divided into two groups: the subjects treated with azelnidipine or temocapril, for 52 weeks. We selected 18 susceptible genes for hypertension and determined their genotypes using TaqMan PCR method. RNA samples were extracted from peripheral blood, and quantitative real time PCR for all genes was performed using TaqMan method. One of the polymorphisms of the RGS2 gene was extracted as being able to influence the effect of these treatments to reduce BP. At eight weeks, BP change showed a significant interaction between the A-638G polymorphism of Regulator of G protein signaling-2 (RGS2) gene and treatment with azelnidipine or temocapril. There was no gene whose expression was associated with BP phenotypes or the polymorphisms of each gene. Conclusions. A-638G polymorphism of the RGS-2 gene could be a predictive factor for therapeutic performance of Ca channel blockers. SAGE-Hindawi Access to Research 2010-08-24 /pmc/articles/PMC2958339/ /pubmed/20981351 http://dx.doi.org/10.4061/2010/196307 Text en Copyright © 2010 Ken Sugimoto et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sugimoto, Ken
Katsuya, Tomohiro
Kamide, Kei
Fujisawa, Tomomi
Shimaoka, Izumi
Ohishi, Mitsuru
Morishita, Ryuichi
Ogihara, Toshio
Rakugi, Hiromi
Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study
title Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study
title_full Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study
title_fullStr Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study
title_full_unstemmed Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study
title_short Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study
title_sort promoter polymorphism of rgs2 gene is associated with change of blood pressure in subjects with antihypertensive treatment: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958339/
https://www.ncbi.nlm.nih.gov/pubmed/20981351
http://dx.doi.org/10.4061/2010/196307
work_keys_str_mv AT sugimotoken promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy
AT katsuyatomohiro promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy
AT kamidekei promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy
AT fujisawatomomi promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy
AT shimaokaizumi promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy
AT ohishimitsuru promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy
AT morishitaryuichi promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy
AT ogiharatoshio promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy
AT rakugihiromi promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy